Men's Health News

RSS

New study indicates pregnancy can double HIV risk in men

Young women of reproductive-age are among those at greatest risk of acquiring HIV, and several studies have suggested that during pregnancy women are even more susceptible to infection.

24 May 2010

Data on serum DNA blood tests for early detection of cancer to be presented at ASCO 2010

Chronix Biomedical today reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. The unique testing algorithms developed by Chronix detected and correctly identified DNA fragments in the blood from dying (apoptotic) cancer cells with 92% sensitivity and 100% specificity in both prostate cancer and breast cancer.

21 May 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.

21 May 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the online-first publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

20 May 2010

Over-expression of Stat5 protein leads to deadly spread of prostate cancer: Study

Researchers from the Kimmel Cancer Center at Jefferson have found that Stat5, a signaling protein previously found to be key to survival of prostate cancer, is also involved in metastasis.

20 May 2010

Significant proportion of men with ED exhibit early signs of CAD: Review

International experts are calling for all men experiencing impotence to undergo thorough medical assessments, after an extensive review showed that a significant proportion of men with erectile dysfunction exhibit early signs of coronary artery disease.

19 May 2010

Researchers develop PHI test to help determine aggressiveness of prostate cancer

Researchers at Johns Hopkins University have developed what could be a promising new test to help determine the aggressiveness of prostate cancer, says a Bay Area urologist who specializes in treating the disease, although patients may not realize any benefits for another decade or longer.

19 May 2010

New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia.

19 May 2010

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Generex Biotechnology Corporation announced today publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. At the end of 2009, the Company announced positive interim results from a Phase II trial being conducted with AE37 in patients with breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 May 2010

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.

18 May 2010

Study reviews impact of focal therapy for low-risk prostate cancer patients

In the July issue of European Urology, the scientific journal of the European Association of Urology, the significance and impact of focal therapy for low-risk cancer patients is discussed in a recent study by S. Eggener et al.

18 May 2010

New DVS radiation measurement device for prostate cancer treatment

John Theurer Cancer Center at Hackensack University Medical Center announced today that it is one of two cancer centers in the tri-state area currently implanting a wireless radiation sensor, known as DVS. John Theurer Cancer Center radiation oncologists can now receive data immediately post- treatment on the precise amount of radiation being delivered to tumors and surrounding tissue for prostate cancer treatments.

18 May 2010

Low testosterone levels can impact sleep quality

At 30 years old, male testosterone levels drop by one to two percent annually. By age 40, men's quality of sleep begins to diminish. Could there be a link between decreased testosterone and reduced sleep?

15 May 2010

Rich Canadian men increase their likelihood of being overweight

In Canada, in stark contrast with the rest of the world, wealthy men increase their likelihood of being overweight with every extra dollar they make. The new study was led by Nathalie Dumas, a graduate student at the University of Montreal Department of Sociology, and presented at the annual conference of the Association francophone pour le savoir.

15 May 2010

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

The effects of multivitamins are most often researched in the elderly. This is one of very few studies to assess the relationship between supplementation with vitamins/minerals and psychological functioning in healthy groups of non-elderly adults. This study shows how a proprietary multivitamin and mineral supplement improves mood and mental performance while also reducing stress, mental tiredness and fatigue in healthy males.

14 May 2010

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.

14 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

25% of adults quit their overactive bladder medication: Study

Study of 5,392 adults found that a quarter had quit their overactive bladder medication, with nine out of ten saying it didn't work as expected or they couldn't tolerate it. A follow-up study found that being a current smoker raised the risk of quitting by 80%, having an enlarged prostate by 74% and believing that bladder medication caused side effects by 111%.

13 May 2010

Researchers develop new technology to manage prostate cancer treatment

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

13 May 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

Men's Health News

New study indicates pregnancy can double HIV risk in men

Data on serum DNA blood tests for early detection of cancer to be presented at ASCO 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Over-expression of Stat5 protein leads to deadly spread of prostate cancer: Study

Significant proportion of men with ED exhibit early signs of CAD: Review

Researchers develop PHI test to help determine aggressiveness of prostate cancer

New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Study reviews impact of focal therapy for low-risk prostate cancer patients

New DVS radiation measurement device for prostate cancer treatment

Low testosterone levels can impact sleep quality

Rich Canadian men increase their likelihood of being overweight

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

25% of adults quit their overactive bladder medication: Study

Researchers develop new technology to manage prostate cancer treatment

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News